We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Pool Corp
POOL
$7.05B
| $425K | ﹤0.01% |
1,860
-2,212
| -54% | -$575K |
|
|
KW
902
DELISTED
Kennedy-Wilson Holdings
KW
| $413K | ﹤0.01% |
42,759
+1,980
| +5% | +$17.8K |
|
|
VRE
903
DELISTED
Veris Residential
VRE
| $403K | ﹤0.01% |
27,055
-232
| -0.9% | -$3.43K |
|
|
CSR
904
Centerspace
CSR
$952M
| $402K | ﹤0.01% |
6,028
+758
| +14% | +$47.6K |
|
905
Innovative Industrial Properties
IIPR
$1.77B
| $389K | ﹤0.01% |
8,204
+2,012
| +32% | +$104K |
|
906
Reliance Steel & Aluminium
RS
$20.6B
| $374K | ﹤0.01% |
1,293
-15
| -1% | -$4.21K |
|
|
PDM
907
Piedmont Realty Trust
PDM
$1.24B
| $371K | ﹤0.01% |
44,473
+4,887
| +12% | +$40.8K |
|
908
RLJ Lodging Trust
RLJ
$1.88B
| $367K | ﹤0.01% |
49,230
-2,897
| -6% | -$21.1K |
|
|
JBGS
909
JBG SMITH
JBGS
$846M
| $365K | ﹤0.01% |
21,450
+414
| +2% | +$7.83K |
|
|
AAT
910
American Assets Trust
AAT
$1.46B
| $349K | ﹤0.01% |
18,421
+853
| +5% | +$16.5K |
|
|
MSC
911
Studio City International Holdings
MSC
$338M
| $348K | ﹤0.01% |
98,050
| – | – |
|
912
Lamb Weston
LW
$7.42B
| $339K | ﹤0.01% |
8,098
| – | – |
|
913
ACM Research
ACMR
$4.51B
| $331K | ﹤0.01% |
8,386
-2,692
| -24% | -$100K |
|
914
Empire State Realty Trust
ESRT
$1B
| $326K | ﹤0.01% |
50,070
+4,272
| +9% | +$30.5K |
|
915
iShares US Treasury Bond ETF
GOVT
$43.7B
| $325K | ﹤0.01% |
14,103
| – | – |
|
|
DEA
916
Easterly Government Properties
DEA
$1.16B
| $322K | ﹤0.01% |
15,188
+2,009
| +15% | +$43.6K |
|
917
Grupo Cibest SA
CIB
$21.2B
| $320K | ﹤0.01% |
5,027
| – | – |
|
|
AIV
918
Aimco
AIV
$377M
| $316K | ﹤0.01% |
53,135
+4,689
| +10% | +$28.1K |
|
919
Campbell Soup
CPB
$6.85B
| $315K | ﹤0.01% |
11,309
| – | – |
|
920
Bloom Energy
BE
$48.2B
| $300K | ﹤0.01% |
+3,450
| New | +$362K |
|
921
F&G Annuities & Life
FG
$3.91B
| $279K | ﹤0.01% |
+9,056
| New | +$283K |
|
|
SAFE
922
Safehold
SAFE
$1.17B
| $272K | ﹤0.01% |
19,892
+922
| +5% | +$13.1K |
|
923
Ciena
CIEN
$46.8B
| $266K | ﹤0.01% |
+1,139
| New | +$221K |
|
924
Rocket Lab Corp
RKLB
$36.6B
| $246K | ﹤0.01% |
+3,522
| New | +$202K |
|
|
NXRT
925
NexPoint Residential Trust
NXRT
$689M
| $242K | ﹤0.01% |
8,055
+493
| +7% | +$15.1K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.